Cook Medical is pleased to announce that the Centers for Medicare & Medicaid Services (CMS) have approved an NTAP (new technology add-on payment) for Hemospray Endoscopic Hemostat when used in the inpatient or acute-care setting.
The NTAP provides an additional payment to hospitals, which limits their financial burden and increases patient access to new technologies.
An NTAP application must meet three criteria in order to be approved: The technology must be considered new, it must be inadequately paid under the existing Medicare Severity-Diagnosis Related Group (MS-DRG) system, and—most important—it must significantly improve clinical outcomes.
Here is an excerpt from the Inpatient Prospective Payment System FY2021, released September 2, 2020:
After consideration of the public comments we received and the information included in the applicant’s new technology add-on payment application, we have determined that Hemospray meets the criteria for approval of the new technology add-on payment. Therefore, we are approving new technology add-on payments for this technology for FY 2021. Cases involving the use of Hemospray that are eligible for new technology add-on payments will be identified by procedure codes XWoG886 (Introduction of mineral-based topical hemostatic agent into upper GI, via natural or artificial opening endoscopic, new technology group 6) and XWoH886 (Introduction of mineral-based topical hemostatic agent into lower GI, via natural or artificial opening endoscopic, new technology group 6). In its application, the applicant estimated that the cost of Hemospray is $2,500.00 per patient. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS-DRG payment for the case. As a result, the maximum new technology add-on payment for a case involving the use of Hemospray is $1,625.00 for FY 2021.
The effective date for the add-on payment is October 1, 2020.